Benchling: $8.5B valuation, IPO Readiness 70, Public. Filed S-1 with the SEC on May 2026 — IPO actively in progress. Track live on The IPO Stack.
Benchling is the R&D cloud platform for life sciences teams to design, track, and analyze experiments — the operating system for biotech and pharmaceutical R&D globally. Valued at $6.1B with $500M+ raised, Benchling is used by 10 of the top 20 pharmaceutical companies including Pfizer, Novartis, and Regeneron. Major healthtech IPO candidate competing with Schrödinger and Dotmatics in the $30B+ life sciences software market.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Benchling IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Benchling is already a public company.
Benchling is valued at $8.5B as of November 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Benchling is already a public company. You can invest by purchasing shares on public stock exchanges.
Benchling scores 70/100 (Grade: B) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Yes — Benchling filed an S-1 registration statement with the SEC on May 11, 2026, indicating an active IPO process.
Benchling has raised $912M in total venture capital and private equity funding, with backing from Andreessen Horowitz, Benchmark, Sequoia Capital.
Benchling's notable investors include Andreessen Horowitz, Benchmark, Sequoia Capital, Coatue, Meritech Capital. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Benchling is a Biotechnology company. Benchling is the R&D cloud platform for life sciences teams to design, track, and analyze experiments — the operating sy.